Inflammation is a possible mediator of the relationship between metabolic syndrome (MetS) and osteoporosis. Palm tocotrienol, an anti-inflammatory agent, has been reported to exert beneficial effects for the treatment of MetS and osteoporosis individually. This study aimed to investigate the potential role of palm tocotrienol in preventing both MetS and bone loss in male rats via alleviating the inflammatory response. In this study, MetS was established in the rats fed with HCHF diet. This was accompanied by bone loss and elevated pro-inflammatory cytokine levels. Supplementation of palm tocotrienol improved MetS parameters, trabecular bone microstructure, bone strength, and reduced pro-inflammatory cytokines in the HCHF rats. A dose-dependent effect of palm tocotrienol was also observed in preventing MetS conditions. In conclusion, palm tocotrienol prevents both MetS and bone loss, possibly through its anti-inflammatory properties.